BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
BridgeBio Pharma (BBIO) has announced it will release its Q4 and full-year 2024 financial results on February 20, 2025. The announcement will include updates on Attruby's commercialization progress and the company's late-stage clinical pipeline. Starting with Q1 results, expected in late April or early May, the company will begin hosting earnings calls, as previously outlined in its JPM presentation.
BridgeBio Pharma (BBIO) ha annunciato che pubblicherà i suoi risultati finanziari del Q4 e dell'intero anno 2024 il 20 febbraio 2025. L'annuncio includerà aggiornamenti sul progresso della commercializzazione di Attruby e sul pipeline clinico in fase avanzata dell'azienda. A partire dai risultati del Q1, previsti per la fine di aprile o l'inizio di maggio, l'azienda inizierà a tenere chiamate sugli utili, come precedentemente delineato nella sua presentazione JPM.
BridgeBio Pharma (BBIO) ha anunciado que publicará sus resultados financieros del Q4 y del año completo 2024 el 20 de febrero de 2025. El anuncio incluirá actualizaciones sobre el progreso de la comercialización de Attruby y el pipeline clínico en fase avanzada de la compañía. A partir de los resultados del Q1, que se esperan a finales de abril o principios de mayo, la compañía comenzará a realizar llamadas sobre ganancias, como se indicó anteriormente en su presentación de JPM.
브릿지바이오 제약 (BBIO)는 2024년 4분기 및 연간 재무 결과를 2025년 2월 20일 발표할 것이라고 발표했습니다. 이 발표에는 Attruby의 상용화 진행 상황 및 회사의 후기 단계 임상 파이프라인에 대한 업데이트가 포함될 것입니다. 1분기 결과는 4월 말 또는 5월 초에 예상되며, 회사는 이전 JPM 발표에서 설명한 대로 수익 전화 회의를 시작할 것입니다.
BridgeBio Pharma (BBIO) a annoncé qu'elle publiera ses résultats financiers du T4 et de l'année complète 2024 le 20 février 2025. L'annonce comprendra des mises à jour sur les progrès de la commercialisation d'Attruby et sur le pipeline clinique de l'entreprise en phase avancée. À partir des résultats du T1, attendus à la fin d'avril ou au début de mai, l'entreprise commencera à organiser des appels de résultats, comme cela a été précédemment indiqué dans sa présentation JPM.
BridgeBio Pharma (BBIO) hat angekündigt, dass es seine Finanzergebnisse für das 4. Quartal und das gesamte Jahr 2024 am 20. Februar 2025 veröffentlichen wird. Die Ankündigung wird Updates zum Fortschritt der Kommerzialisierung von Attruby und zur klinischen Pipeline des Unternehmens in der späten Phase enthalten. Mit den Ergebnissen des 1. Quartals, die Ende April oder Anfang Mai erwartet werden, wird das Unternehmen beginnen, Gewinnanrufe abzuhalten, wie zuvor in seiner JPM-Präsentation dargelegt.
- None.
- None.
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby’s commercialization progress and its late-stage clinical pipeline.
The Company will begin hosting earnings calls with the Q1 earnings release, expected in late April or early May, as outlined in its JPM presentation.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Media Contact:
Bubba Murarka
contact@bridgebio.com
(650)-789-8220
FAQ
When will BridgeBio (BBIO) release its Q4 2024 earnings?
Will BridgeBio (BBIO) provide updates on Attruby commercialization in its Q4 2024 report?
When will BridgeBio (BBIO) start hosting earnings calls?
What updates will be included in BridgeBio's (BBIO) Q4 2024 earnings report?
